At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AMLX Amylyx Pharmaceuticals
Pre-Mkt 04-16 06:58:42 EDT
17.12
+0.20
+1.18%
盘前17.24
+0.12+0.70%
06:55 EDT
High17.16Low16.59Vol815.84K
Open16.93D1 Closing16.92Amplitude3.37%
Mkt Cap1.89BTradable Cap1.12BTotal Shares110.54M
T/O13.81MT/O Rate1.25%Tradable Shares65.45M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Amylyx to present at Needham Virtual Healthcare Conference
Reuters  ·  04-08
Amylyx to present at Needham Virtual Healthcare Conference
A Look At Amylyx Pharmaceuticals (AMLX) Valuation As Avexitide Hits A Key Phase 3 LUCIDITY Milestone
Simply Wall St.  ·  04-07
A Look At Amylyx Pharmaceuticals (AMLX) Valuation As Avexitide Hits A Key Phase 3 LUCIDITY Milestone
Amylyx Pharmaceuticals Price Target Maintained With a $34.00/Share by HC Wainwright & Co.
Dow Jones  ·  03-25
Amylyx Pharmaceuticals Price Target Maintained With a $34.00/Share by HC Wainwright & Co.
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday Amid Economic Data Releases
MT Newswires Live  ·  03-24
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday Amid Economic Data Releases
Amylyx completes enrollment in Phase 3 Lucidity trial of avexitide
TIPRANKS  ·  03-24
Amylyx completes enrollment in Phase 3 Lucidity trial of avexitide
Amylyx completes enrollment of 78 participants in Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia
Reuters  ·  03-24
Amylyx completes enrollment of 78 participants in Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia
Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 Lucidity Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia
THOMSON REUTERS  ·  03-24
Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 Lucidity Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia
Amylyx Pharmaceuticals Inc - Topline Data Readout for Lucidity Trial Anticipated in Q3 2026
THOMSON REUTERS  ·  03-24
Amylyx Pharmaceuticals Inc - Topline Data Readout for Lucidity Trial Anticipated in Q3 2026
Amylyx Pharmaceuticals Is Maintained at Buy by Guggenheim
Dow Jones  ·  03-19
Amylyx Pharmaceuticals Is Maintained at Buy by Guggenheim
Stock Track | Amylyx Pharmaceuticals Soars 5.24% Intraday After H.C. Wainwright Raises Price Target to $34
Stock Track  ·  03-05
Stock Track | Amylyx Pharmaceuticals Soars 5.24% Intraday After H.C. Wainwright Raises Price Target to $34
Amylyx Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones  ·  03-05
Amylyx Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Amylyx price target raised to $34 from $28 at H.C. Wainwright
TIPRANKS  ·  03-04
Amylyx price target raised to $34 from $28 at H.C. Wainwright
Amylyx Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $34 From $28
THOMSON REUTERS  ·  03-04
Amylyx Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $34 From $28
Stock Track | Amylyx Pharmaceuticals Plummets 5.52% Intraday Following Shelf Offering Announcement
Stock Track  ·  03-03
Stock Track | Amylyx Pharmaceuticals Plummets 5.52% Intraday Following Shelf Offering Announcement
Amylyx Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary
Reuters  ·  03-03
Amylyx Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary
Amylyx files automatic mixed securities shelf
TIPRANKS  ·  03-03
Amylyx files automatic mixed securities shelf
Amylyx Pharmaceuticals Inc - Files for Mixed Shelf Offering; Size Not Disclosed - SEC Filing
THOMSON REUTERS  ·  03-03
Amylyx Pharmaceuticals Inc - Files for Mixed Shelf Offering; Size Not Disclosed - SEC Filing
Amylyx reports Q4 EPS (30c), consensus (34c)
TIPRANKS  ·  03-03
Amylyx reports Q4 EPS (30c), consensus (34c)
Earnings Flash (AMLX) Amylyx Pharmaceuticals Posts Q4 Net Loss $0.30 a Share, vs. FactSet Est of $0.29 Loss
MT Newswires Live  ·  03-03
Earnings Flash (AMLX) Amylyx Pharmaceuticals Posts Q4 Net Loss $0.30 a Share, vs. FactSet Est of $0.29 Loss
Amylyx Pharmaceuticals Q4 net loss beats estimates
Reuters  ·  03-03
Amylyx Pharmaceuticals Q4 net loss beats estimates

Introduction

Company Name.
Amylyx Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Issue price:
--